Back to Authors

Irwig, Michael S.

0000-0003-1231-1941

A5036244362 | I1316535847

Mayo Clinic

Beth Israel Deaconess Medical Center

Citations 2

Revisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy

Transgender Health | February 12, 2024 | Volume: 9 | Issue: 6 | Pages: 463-465

10.1089/trgh.2023.0209 | PMID 39735380

Injectable estrogens are options for gender-affirming hormone therapy per guidelines, which suggest intramuscular dosages of 5–30 mg every 2 weeks or 2–10 mg weekly with estradiol cypionate or valerate interchangeably. Data among transgender and gender-diverse patients are limited due to local unavailability and concerns around laboratory assay variability and estradiol (E2) level fluctuation. We note a concerning trend where patients are prescribed high-dose injections based on the guidelines leading to serum E2 levels well above the range recommended in the same guidelines. Our review indicates that 5 mg weekly or lower should be prescribed when initiating injectable estrogens to avoid supraphysiologic E2 levels.
Standards of Care for the Health of Transgender and Gender Diverse People, Version 8

International Journal of Transgender Health | September 6, 2022 | Volume: 23 | Issue: sup1 | Pages: S1-S259

10.1080/26895269.2022.2100644 | PMID 36238954